Standard BioTools Inc. reported preliminary and unaudited combined company revenue for the full year 2025 of approximately $185 million.
Revenue from continuing operations for the same period amounted to around $85 million.
The company exceeded expectations for both combined and continuing operations in 2025.
CEO Michael Egholm highlighted the steady execution and efforts towards profitability in 2025.
2025 Revenue
Full year 2025 revenue reached approximately $185 million, exceeding guidance and expectations.
Continuing Operations
Revenue from continuing operations in 2025 amounted to about $85 million, showing a strong performance.
Path to Profitability
The company took targeted actions to streamline operations, enhancing the cost structure and driving rigor across the organization.
- Standard BioTools reported a positive financial performance in 2025, with revenue figures exceeding projections.
- The focus on profitability and operational efficiency in 2025 has positioned the company for sustained growth in the future.
- The pending sale of SomaLogic to Illumina is expected to provide the company with around $550 million in cash, enhancing its strategic flexibility.
Standard BioTools has demonstrated strong financial performance in 2025, exceeding revenue targets and enhancing operational efficiency. The pending sale of SomaLogic to Illumina presents opportunities for further growth and strategic expansion in 2026.